Neuro-Oncology · 2019 · 34 citations · 24 references
MedicineOncologyPharmacologyCancer PharmacologyDrug DiscoveryMolecular OncologyCancer MetabolismEnzyme InhibitionGlioblastomaMolecular Tumor ProfilingOncology PharmacologyDihydroorotate Dehydrogenase InhibitorsGlioblastoma ChemotherapyGlioblastoma Drug TherapyGlioblastoma Targeted TherapyHigh Throughput BioassaysPyrimidine BiosynthesisPyrimidine Synthesis InhibitorsTumor Cell Proliferation
BACKGROUND: Glioblastoma-initiating cells (GICs) comprise a tumorigenic subpopulation of cells that are resistant to radio- and chemotherapies and are responsible for cancer recurrence. The aim of this study was to identify novel compounds that specifically eradicate GICs using a high throughput drug screening approach. METHODS: We performed a cell proliferation/death-based drug screening using 10 560 independent compounds. We identified dihydroorotate dehydrogenase (DHODH) as a target protein of hit compound 10580 using ligand-fishing and mass spectrometry analysis. The medical efficacy of 10580 was investigated by in vitro cell proliferation/death and differentiation and in vivo tumorigenic assays. RESULTS: Among the effective compounds, we identified 10580, which induced cell cycle arrest, decreased the expression of stem cell factors in GICs, and prevented tumorigenesis upon oral administration without any visible side effects. Mechanistic studies revealed that 10580 decreased pyrimidine nucleotide levels and enhanced sex determining region Y-box 2 nuclear export by antagonizing the enzyme activity of DHODH, an essential enzyme for the de novo pyrimidine synthesis. CONCLUSION: In this study, we identified 10580 as a promising new drug against GICs. Given that normal tissue cells, in particular brain cells, tend to use the alternative salvage pathway for pyrimidine synthesis, our findings suggest that 10580 can be used for glioblastoma therapy without side effects.Key Points1. Chemical screening identified 10580 as a novel GIC-eliminating drug that targets DHODH, an essential enzyme for the de novo pyrimidine synthesis pathway. 2. Compound 10580 induced cell cycle arrest, apoptosis, and differentiation in GICs.
24
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp, Warren Mason, Martin J. van den Bent et al. · New England Journal of Medicine · 2005 · 21.6K citations · Full text
Ethan Cerami, Jianjiong Gao, Uğur Doğrusöz et al. · Cancer Discovery · 2012 · 18.4K citations · Full text
Medicine, Bioinformatics, Oncology +15
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao, Bülent Arman Aksoy, Uğur Doğrusöz et al. · Science Signaling · 2013 · 15.9K citations · Full text
Medicine, Bioinformatics, Oncology +17
Roger Stupp, Monika E. Hegi, Warren Mason et al. · The Lancet Oncology · 2009 · 7.8K citations
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
Piyush B. Gupta, Tamer T. Önder, Guozhi Jiang et al. · Cell · 2009 · 2.4K citations · Full text